Contrasting of Jounce Therapeutics Inc. (JNCE) and Marker Therapeutics Inc. (NASDAQ:MRKR)

As Biotechnology companies, Jounce Therapeutics Inc. (NASDAQ:JNCE) and Marker Therapeutics Inc. (NASDAQ:MRKR) are our subject to contrast. And more specifically their dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jounce Therapeutics Inc. 65.20M 3.47 27.38M -1.07 0.00
Marker Therapeutics Inc. N/A 11594.95 15.08M -1.28 0.00

In table 1 we can see Jounce Therapeutics Inc. and Marker Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 has Jounce Therapeutics Inc. and Marker Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jounce Therapeutics Inc. -41.99% -28.4% -13.1%
Marker Therapeutics Inc. 0.00% -662.2% -295.8%


Jounce Therapeutics Inc. has a Current Ratio of 3.1 and a Quick Ratio of 3.1. Competitively, Marker Therapeutics Inc.’s Current Ratio is 1.2 and has 1.2 Quick Ratio. Jounce Therapeutics Inc.’s better ability to pay short and long-term obligations than Marker Therapeutics Inc.

Insider and Institutional Ownership

The shares of both Jounce Therapeutics Inc. and Marker Therapeutics Inc. are owned by institutional investors at 73.7% and 43.5% respectively. Insiders owned roughly 0.8% of Jounce Therapeutics Inc.’s shares. Insiders Comparatively, owned 22.8% of Marker Therapeutics Inc. shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Jounce Therapeutics Inc. 5.24% 10.26% 3.36% -42.03% -77.43% 37.09%
Marker Therapeutics Inc. -3.11% 17.96% -10.86% -12.11% 96.23% 12.43%

For the past year Jounce Therapeutics Inc.’s stock price has bigger growth than Marker Therapeutics Inc.


On 6 of the 9 factors Jounce Therapeutics Inc. beats Marker Therapeutics Inc.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. Its lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. The company is also developing JTX-4014, an anti-PD-1 antibody. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is also advancing various peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In addition, it develops a proprietary DNA expression technology, known as PolyStart, to improve the ability of the cellular immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.